BRIEF-Acumen Pharmaceuticals Completes Enrollment Of Altitude-Ad, A Phase 2 Clinical Trial Of Sabirnetug (Acu193) In Early Alzheimer’S Disease

Reuters
26 Mar
BRIEF-Acumen Pharmaceuticals Completes Enrollment Of Altitude-Ad, A Phase 2 Clinical Trial Of Sabirnetug (Acu193) In Early Alzheimer’S Disease

March 26 (Reuters) - Acumen Pharmaceuticals Inc ABOS.O:

  • ACUMEN PHARMACEUTICALS COMPLETES ENROLLMENT OF ALTITUDE-AD, A PHASE 2 CLINICAL TRIAL OF SABIRNETUG (ACU193) IN EARLY ALZHEIMER’S DISEASE

  • ACUMEN PHARMACEUTICALS INC - TOPLINE RESULTS EXPECTED IN LATE 2026

Source text: ID:nGNX3Vt03J

Further company coverage: ABOS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10